Gregory M. Weinhoff Sells 16,619 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 16,619 shares of the business’s stock in a transaction on Wednesday, September 25th. The stock was sold at an average price of $15.69, for a total transaction of $260,752.11. Following the completion of the transaction, the insider now directly owns 206,750 shares in the company, valued at approximately $3,243,907.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Centessa Pharmaceuticals Stock Up 0.8 %

NASDAQ CNTA opened at $15.79 on Friday. The company has a quick ratio of 13.29, a current ratio of 13.29 and a debt-to-equity ratio of 0.27. Centessa Pharmaceuticals plc has a 52 week low of $5.15 and a 52 week high of $17.59. The firm has a market capitalization of $1.59 billion, a price-to-earnings ratio of -11.12 and a beta of 1.44. The company has a fifty day moving average of $13.01 and a two-hundred day moving average of $10.84.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). On average, analysts predict that Centessa Pharmaceuticals plc will post -1.62 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on CNTA. B. Riley initiated coverage on Centessa Pharmaceuticals in a research report on Thursday, September 19th. They set a “buy” rating and a $33.00 price objective for the company. Guggenheim lifted their price objective on Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. BMO Capital Markets increased their target price on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research report on Monday, September 16th. Jefferies Financial Group raised their target price on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $14.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $25.17.

Institutional Trading of Centessa Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of CNTA. Quarry LP purchased a new stake in shares of Centessa Pharmaceuticals during the fourth quarter valued at $48,000. Sandia Investment Management LP purchased a new stake in Centessa Pharmaceuticals in the 2nd quarter valued at about $90,000. Fred Alger Management LLC bought a new position in Centessa Pharmaceuticals in the 2nd quarter worth about $99,000. EntryPoint Capital LLC purchased a new position in shares of Centessa Pharmaceuticals during the first quarter worth approximately $109,000. Finally, Trexquant Investment LP bought a new stake in shares of Centessa Pharmaceuticals during the fourth quarter valued at approximately $114,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.